Vaxxas - development of HD-micro array patch (map) to deliver a vaccine against a pandemic strain of influenza, H5N1.
Active Definitive Contract Awarded Last action
- Contract number
- 75A50120C00180
- Awardee
-
Vaxxas PTY LTD UEI Y7KNH2UW56R5 Part of The University Of Queensland
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $29,594,472
Award facts
- Contract value 100% obligated
- $29,594,471.80 Current and potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Australia
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,072,500 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $6,801,291 | |
| Other Administrative Action | $0 | |
| Original award | $21,720,681 |
About this award
The U.S. Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $29.6 million definitive cost-plus-fixed-fee contract to Vaxxas PTY LTD on September 29, 2020, to develop a high-definition micro array patch (HD-MAP) delivery system for administering H5N1 pandemic influenza vaccines. The contract is scheduled for completion by December 30, 2026, with performance occurring in Australia. Vaxxas is a subsidiary of The University of Queensland's Research & Innovation division, a leading Australian research institution with extensive experience in U.S. government-funded biomedical and defense research. This award reflects ASPR's commitment to advancing innovative vaccine delivery technologies as part of pandemic preparedness capabilities.
The program has engaged multiple specialized subcontractors to support development and clinical advancement. Key subcontractors include Latham Biopharm Group (program management and risk mitigation), Capital Edge Consulting (contracts management and financial oversight), and Inklein LLC (market research on stakeholder perspectives). Clinical development activities have progressed to Phase I trials, supported by subcontracts with the University of the Sunshine Coast and Vismederi S.R.L. for clinical trial management and manufacturing support. Additional subcontractors including Hargrove Engineers & Constructors have provided engineering and design services. The contract structure incorporates multiple sub-awards issued in 2023 and 2024, demonstrating active program execution focused on advancing the HD-MAP delivery system toward clinical application.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Subcontractor not on record | $1,580,030 | |
| Vismederi S.R.L. | $189,050 | |
| Capital Edge Consulting, LLC | $288,914 | |
| Subcontractor not on record | $370,324 | |
| University Of The Sunshine Coast | $2,263,757 | |
| Hargrove & Associates Inc. | $195,000 | |
| Subcontractor not on record | $355,371 | |
| Subcontractor not on record | $259,527 |
Quick answers
Who was awarded contract 75A50120C00180?
75A50120C00180 was awarded to Vaxxas PTY LTD by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 29, 2020.
How much is contract 75A50120C00180 worth?
The government has obligated $29,594,472 on 75A50120C00180.
Was contract 75A50120C00180 competed?
The extent of competition for 75A50120C00180 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award